3B/BMC Announce Global Strategy to Invalidate ResMed (RMD) Patent Portfolio – Simultaneous Actions Filed in the United States, Germany and China

BEIJING, July 31, 2014 /PRNewswire/ — BMC Medical Co., Ltd. and 3B Medical, Inc. (“3B/BMC”) announced today a global strategy to go on offense and seek to invalidate portions of ResMed’s patent portfolio in China, Germany and the

Related posts